tiprankstipranks
Trending News
More News >
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market

Innate Pharma (IPHA) Income Statement

Compare
129 Followers

Innate Pharma Income Statement

Last quarter (Q2 2025), Innate Pharma's total revenue was €4.86M, a decrease of -86.25% from the same quarter last year. In Q2, Innate Pharma's net income was €-21.34M. See Innate Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
€ 12.62M€ 51.90M€ 57.67M€ 12.11M€ 69.77M
Gross Profit
€ 12.62M€ 5.62M€ 6.01M€ -22.30M€ 20.07M
Operating Expenses
€ 64.20M€ 18.29M€ 63.44M€ 25.52M€ 18.99M
Depreciation and Amortization
€ 1.99M€ 5.09M€ 45.41M€ 4.60M€ 12.23M
EBITDA
€ -46.91M€ -1.84M€ -12.28M€ -43.23M€ 13.30M
Operating Income
€ -51.58M€ -12.67M€ -57.42M€ -47.83M€ 1.08M
Other Income/Expenses
€ 2.10M€ 5.10M€ -547.00K€ 2.35M€ -1.91M
Pretax Income
€ -49.47M€ -7.57M€ -57.97M€ -45.48M€ -829.00K
Net Income
€ -49.47M€ -7.57M€ -58.10M€ -52.81M€ -63.98M
Per Share Metrics
Basic EPS
€ -0.61€ -0.09€ -0.73€ -0.57€ -0.01
Diluted EPS
€ -0.61€ -0.09€ -0.73€ -0.57€ -0.01
Weighted Average Shares Outstanding
81.05M 84.11M 79.59M 79.54M 78.93M
Weighted Average Shares Outstanding (Diluted)
81.05M 84.11M 79.64M 79.54M 78.93M
Currency in EUR

Innate Pharma Earnings and Revenue History